<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56295">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373280</url>
  </required_header>
  <id_info>
    <org_study_id>B-1407/259-005</org_study_id>
    <nct_id>NCT02373280</nct_id>
  </id_info>
  <brief_title>The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection</brief_title>
  <official_title>A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the eradication success rate between 10-days sequential therapy and 7-days
      tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As increasing antimicrobial resistance in Korea, the effectiveness of empirical Helicobacter
      pylori (H. pylori) therapies have been declined. Recently, 10-day sequential therapy was not
      sufficient to overcome tough situation for H. pylori eradication.

      Thus, in this study, the investigators evaluated the efficacy of H. pylori eradication
      between a 7 days tailored therapy (7 day PPI based triple therapy, bismuth quadruple therapy
      or moxifloxacin contained triple therapy) for H. pylori infection based on the results of
      antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC)
      and the 10 day sequential therapy for the first eradication of H. pylori infection, and the
      investigators analyzed the prevalence of the antibiotic resistance in the tailored therapy
      group.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the percentage of participants with successful H. pylori eradication in each groups</measure>
    <time_frame>6 weeks after completion of eradication</time_frame>
    <description>The efficacy of H. pylori eradication between a 7 days tailored therapy for H. pylori infection based on the results of antimicrobial resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the 10 days therapy as first eradication regimen.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Helicobacter Infection</condition>
  <arm_group>
    <arm_group_label>10 day sequential group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After proving H. pylori infection, the participant will receive the empirical 10 day sequential regimen (Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)+amoxicillin® 1 g bid 5 days (D1-D5)+clarithromycin, klaricid® 500mg bid 5 days (D6-D10)+metronidazole, flasinyl® 500mg tid 5 days (D6-D10) for treatment of H. pylori infection in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 days tailored PPI triple therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day tailored regimen [PPI triple therapy (Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+amoxicillin® 1 g bid 7 days (D1-D7)+clarithromycin, klaricid® 500mg bid 7 days (D1-D7)] in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 days tailored EBMT therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day bismuth quadruple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, denol® 300 mg qid 7 days (D1-D7)+Metronidazole, flasinyl® 500 mg tid 7 days (D1-D7)+Tetracycline® 500 mg qid 7 days (D1-D7)] in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 days tailored MEA therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day moxifloxacin triple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)+Amoxicillin® 1 g bid 7 days (D1-D7)] in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)</intervention_name>
    <description>In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).</description>
    <arm_group_label>10 day sequential group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>7 day tailored therapy based on antimicrobial susceptibility testing</intervention_name>
    <description>The participants will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. The resistance to amoxicillin, clarithromycin, metronidazole, tetracycline and moxifloxacin will be evaluated. Based on antimicrobial susceptibility testing, the participants received PPI based triple therapy[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)] or moxifloxacin triple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)].</description>
    <arm_group_label>7 days tailored PPI triple therapy group</arm_group_label>
    <arm_group_label>7 days tailored EBMT therapy group</arm_group_label>
    <arm_group_label>7 days tailored MEA therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI based triple therapy [Esomeprazole, amoxicillin, clarithromycin]</intervention_name>
    <arm_group_label>7 days tailored PPI triple therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bismuth quadruple therapy [Esomeprazole, Tri potassium dicitrate bismuthate, Metronidazole, Tetracycline]</intervention_name>
    <arm_group_label>7 days tailored EBMT therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]</intervention_name>
    <arm_group_label>7 days tailored MEA therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients who proved H. pylori infection following three methods

               1. positive rapid urease test (CLOtest)

               2. histologic evidence of H. pylori by modified Giemsa staining

               3. positive Urea breath test

          -  Male and female Korean Adult (Aged ≥ 18 years)

        Exclusion Criteria:

          -  Patients who received eradication therapy for H. pylori infection, previously

          -  H. pylori eradication failure because of poor compliance

          -  the administration of antibiotics or the consumption of bismuth salts within 4 weeks
             or the administration of a proton pump inhibitor (PPI) within 2 weeks

          -  Advanced gastric cancer or other malignancy

          -  Abnormal liver function or liver cirrhosis

          -  Abnormal renal function or chronic kidney disease

          -  Other severe concurrent diseases

          -  Previous allergic reactions to the study drugs

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nayoung Kim, M.D., Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 19, 2016</lastchanged_date>
  <firstreceived_date>February 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Nayoung Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>tailored therapy</keyword>
  <keyword>eradication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
